ClinicalTrials.gg
CompletedNCT05355818DELTA TEENUpdated Aug 21, 2026Results posted

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

A Phase 3 interventional study of Delgocitinib and Cream vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 37 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
7th of 12
98 · median 178
Started
2022
with 2 others
Phase 3
7 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 3, and was the 10th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in adolescents aged 12-17 years. At each visit to the clinic, the doctor will assess the severity and extent of CHE, and during the trial, the adolescents will assess their CHE signs and symptoms as well as quality of life.

The trial will last up to 22 weeks and has a 1-4 week screening period, a 16-week treatment period and a 2- week follow-up period. During the treatment period, each adolescent participant will use either the delgocitinib cream or cream vehicle twice daily.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12 to 17 years at screening and baseline.
  • Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as moderate to severe at screening and baseline according to IGA CHE (i.e. an IGA-CHE score of 3 or 4).
  • Subjects who have a documented recent history of inadequate response to treatment with topical (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).

    • Inadequate response is defined as a history of failure to achieve and maintain a low disease activity state (comparable to an IGA-CHE score of ≤2) despite treatment with a daily regimen of TCS of class III-IV (potent to very potent) for Europe and Australia and class IV-I (medium potency to very/ultra-high potency) for Canada, applied for at least 28 days or for the maximum duration recommended by the product prescribing information, whichever is shorter.
    • Important side effects or safety risks are those that outweigh the potential treatment benefits and include intolerance to treatment, reactions, and significant skin atrophy as assessed by the physician.

Exclusion criteria

Exclusion Criteria:

  • Concurrent skin diseases on the hands, e.g. tinea manuum.
  • infection (e.g. impetiginised hand eczema) on the hands.
  • Systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), or within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
  • Use of tanning beds, phototherapy (e.g. ultraviolet B (UVB), ultraviolet A1 (UVA1), psoralen ultraviolet A (PUVA)), or bleach baths on the hands within 28 days prior to baseline.
  • Previous or current treatment with JAK inhibitors (including delgocitinib/LEO 124249), systemic or topical.
  • Cutaneously applied treatment with immunomodulators (e.g. PDE-4 inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
  • Other cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
  • Any disorder which is not stable and could:

    • Affect the safety of the subject throughout the trial.
    • Impede the subject's ability to complete the trial. Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders, and major physical impairment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream

    Delgocitinib cream 20 mg/g twice daily

    Drug: Delgocitinib

  • Placebo comparator
    Cream vehicle

    Cream vehicle twice daily

    Drug: Cream vehicle

Interventions

  • Cream for topical application

  • DrugCream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.

06

What researchers measure

Primary outcomes

  1. Number of Participants With IGA-CHE Treatment Success at Week 16

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

    Time frame: Week 16

Secondary outcomes

  1. Number of Participants With HECSI-90 at Week 16

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

    Time frame: Week 16

  2. Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'itch' component for participants with a baseline HESD itch score (weekly average) of ≥4 points.

    Time frame: Week 16

  3. Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'pain' component for participants with a baseline HESD pain score (weekly average) of ≥4 points.

    Time frame: Week 16

  4. Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' The final HESD score is an average of these 6 individual scores. This endpoint will only assess the score for participants with a baseline HESD itch score (weekly average) of ≥4 points.

    Time frame: Week 16

  5. Number of Participants With IGA-CHE Treatment Success at Week 2

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

    Time frame: Week 2

  6. Number of Participants With IGA-CHE Treatment Success at Week 4

    The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

    Time frame: Week 4

  7. Number of Participants With IGA-CHE Treatment Success at Week 8

    The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

    Time frame: Week 8

  8. Number of Participants With IGA-CHE Treatment Success at Week 12

    The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

    Time frame: Week 12

  9. Change in CDLQI Score From Baseline to Week 16

    The Children's Dermatology Life Quality Index (CDLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. Each question is scored from 0 (no impact) to 3 (high impact). The CDLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.

    Time frame: Week 16

  10. Number of Treatment Emergent AEs From Baseline up to Week 18

    An adverse event (AE) will be considered treatment emergent if started after the first application of treatment, or started before the first application of treatment and worsened in severity after treatment.

    Time frame: Week 18

07

Results

Posted Jul 2, 2025

Participant flow

This trial was conducted at sites in 7 countries (Australia, Belgium, Canada, Spain, France, United Kingdom, and Poland).

Participant flow — Overall Study
MilestoneDelgocitinib CreamCream Vehicle
Started7424
Completed7121
Not completed33
Withdrew: Adverse event11
Withdrew: Lack of efficacy21
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNumber of Participants With IGA-CHE Treatment Success at Week 16

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Treatment Success at Week 16
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With IGA-CHE Treatment Success at Week 16477
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Bayesian · Diff. in proportion of responders in %: 37.9There is no confidence interval when performing Bayesian analyses - instead a 95% credibility interval is used: 13.5% to 58.2%.
SecondaryNumber of Participants With HECSI-90 at Week 16

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With HECSI-90 at Week 16
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With HECSI-90 at Week 16539
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Bayesian · Diff. in proportion of responders in %: 36.4There is no confidence interval when performing Bayesian analyses - instead a 95% credibility interval is used: 12.3% to 59.9%.
SecondaryNumber of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'itch' component for participants with a baseline HESD itch score (weekly average) of ≥4 points.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16357
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Bayesian · Diff. in proportion of responders in %: 31.7There is no confidence interval when performing Bayesian analyses - instead a 95% credibility interval is used: 5.6% to 51.1%.
SecondaryNumber of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'pain' component for participants with a baseline HESD pain score (weekly average) of ≥4 points.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16315
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Bayesian · Diff. in proportion of responders in %: 31.2There is no confidence interval when performing Bayesian analyses - instead a 95% credibility interval is used: 8.7% to 49.4%
SecondaryNumber of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' The final HESD score is an average of these 6 individual scores. This endpoint will only assess the score for participants with a baseline HESD itch score (weekly average) of ≥4 points.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16305
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Bayesian · Diff. in proportion of responders in %: 25.1There is no confidence interval when performing Bayesian analyses - instead a 95% credibility interval is used: 3.9% to 42.3%.
SecondaryNumber of Participants With IGA-CHE Treatment Success at Week 2

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

Time frame:
Week 2
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Treatment Success at Week 2
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With IGA-CHE Treatment Success at Week 2161
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Regression, Logistic · p = 0.0054 · Risk difference (rd): 17.47 · 95% CI 5.16 to 29.78Risk difference estimated using logistic regression stratified by baseline IGA-CHE score.
SecondaryNumber of Participants With IGA-CHE Treatment Success at Week 4

The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Treatment Success at Week 4
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With IGA-CHE Treatment Success at Week 4284
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Regression, Logistic · p = 0.0248 · Risk difference (rd): 21.21 · 95% CI 2.69 to 39.72Risk difference estimated using logistic regression stratified by baseline IGA-CHE score.
SecondaryNumber of Participants With IGA-CHE Treatment Success at Week 8

The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Treatment Success at Week 8
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With IGA-CHE Treatment Success at Week 8369
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Regression, Logistic · p = 0.3320 · Risk difference (rd): 11.08 · 95% CI -11.30 to 33.46Risk difference estimated using logistic regression stratified by baseline IGA-CHE score.
SecondaryNumber of Participants With IGA-CHE Treatment Success at Week 12

The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Treatment Success at Week 12
ParticipantsDelgocitinib CreamCream Vehicle
Number of Participants With IGA-CHE Treatment Success at Week 12436
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · Regression, Logistic · p = 0.0016 · Risk difference (rd): 33.02 · 95% CI 12.51 to 53.52Risk difference estimated using logistic regression stratified by baseline IGA-CHE score.
SecondaryChange in CDLQI Score From Baseline to Week 16

The Children's Dermatology Life Quality Index (CDLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. Each question is scored from 0 (no impact) to 3 (high impact). The CDLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.

Time frame:
Week 16
Reported as:
Least squares mean · score on a scale
Change in CDLQI Score From Baseline to Week 16
score on a scaleDelgocitinib CreamCream Vehicle
Change in CDLQI Score From Baseline to Week 16-5.57 ± 0.44-2.92 ± 0.78
Statistical analysis
  • Delgocitinib Cream vs Cream Vehicle · ANCOVA · p = 0.0038 · Mean difference (net): -2.65 · 95% CI -4.42 to -0.88
SecondaryNumber of Treatment Emergent AEs From Baseline up to Week 18

An adverse event (AE) will be considered treatment emergent if started after the first application of treatment, or started before the first application of treatment and worsened in severity after treatment.

Time frame:
Week 18
Reported as:
Number · events
Number of Treatment Emergent AEs From Baseline up to Week 18
eventsDelgocitinib CreamCream Vehicle
Number of Treatment Emergent AEs From Baseline up to Week 187719

Adverse events

Collected over Treatment emergent adverse events were collected during the 16 weeks of treatment + 2 weeks of follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib Cream0/74 (0%)0/74 (0%)17/74 (23%)
Cream Vehicle0/24 (0%)0/24 (0%)4/24 (16.7%)
Most frequent other events
Most frequent other events
EventDelgocitinib CreamCream Vehicle
NasopharyngitisInfections and infestations10/744/24
Upper respiratory tract infectionInfections and infestations5/740/24
HeadacheNervous system disorders4/741/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Delgocitinib CreamCream VehicleTotal
<=18 years742498
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Delgocitinib CreamCream VehicleTotal
Mean14.6 ± 1.714.7 ± 1.614.6 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib CreamCream VehicleTotal
Female461258
Male281240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib CreamCream VehicleTotal
Hispanic or Latino808
Not Hispanic or Latino622183
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delgocitinib CreamCream VehicleTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American202
White692089
More than one race000
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(participants)Delgocitinib CreamCream VehicleTotal
Canada617
Belgium202
Poland23932
United Kingdom527
Australia10414
France11516
Spain17320
IGA-CHE score
IGA-CHE score(Participants)Delgocitinib CreamCream VehicleTotal
Clear000
Almost clear000
Mild000
Moderate561874
Severe18624
HECSI score
HECSI score(scores on a scale)Delgocitinib CreamCream VehicleTotal
Mean70.9 ± 37.876.2 ± 39.772.2 ± 38.1

4 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • LEO Pharma investigational site
    Darlinghurst, 2010, Australia
  • LEO Pharma investigational site
    Mitcham, 3132, Australia
  • LEO Pharma investigational site
    Phillip, 2606, Australia
  • LEO Pharma investigational site
    Woolloongabba, 4102, Australia
  • LEO Pharma investigational site
    Brussels, 1200, Belgium
  • LEO Pharma investigational site
    Ghent, 9000, Belgium
  • LEO Pharma investigational site
    Gilly, 6060, Belgium
  • LEO Pharma investigational site
    Liège, 4000, Belgium
  • LEO Pharma investigational site
    Edmonton, T6G 1C3, Canada
  • LEO Pharma investigational site
    Fredericton, E3B 1G9, Canada
  • LEO Pharma investigational site
    Kingston, K7L 2V7, Canada
  • LEO Pharma investigational site
    Montreal, H3T 1C5, Canada
  • LEO Pharma investigational site
    Red Deer, T4P1K4, Canada
  • LEO Pharma investigational site
    St. John's, NL A1E 1V4, Canada
  • LEO Pharma investigational site
    Toronto, M2N 3A6, Canada
  • LEO Pharma investigational site
    Winnipeg, R3C 0N2, Canada
  • LEO Pharma investigational site
    Martigues, Bouches-du-Rhône 13500, France
  • LEO Pharma investigational site
    Nice, 06000, France
  • LEO Pharma investigational site
    Reims, 51100, France
  • LEO Pharma investigational site
    Toulouse, 31059, France
  • LEO Pharma investigational site
    Chorzów, 41-516, Poland
  • LEO Pharma investigational site
    Krakow, 30-002, Poland
  • LEO Pharma investigational site
    Krakow, 30-033, Poland
  • LEO Pharma investigational site
    Krakow, 31-011, Poland
  • LEO Pharma investigational site
    Warsaw, 02-625, Poland
  • LEO Pharma investigational site
    Wroclaw, 51-503, Poland
  • LEO Pharma investigational site
    Alicante, 03010, Spain
  • LEO Pharma investigational site
    Barcelona, 08041, Spain
  • LEO Pharma investigational site
    Cadiz, 11009, Spain
  • LEO Pharma investigational site
    Esplugues de Llobregat, 08950, Spain
  • LEO Pharma investigational site
    Fuenlabrada, 28942, Spain
  • LEO Pharma investigational site
    Granada, 18016, Spain
  • LEO Pharma investigational site
    Ipswich, IP4 5PD, United Kingdom
  • LEO Pharma investigational site
    Kings Lynn, PE30 4ET, United Kingdom
  • LEO Pharma investigational site
    Lincoln, LN2 5QY, United Kingdom
  • LEO Pharma investigational site
    London, SW10 9NH, United Kingdom
  • LEO Pharma investigational site
    Walsall, WS2 9PS, United Kingdom
09

References and documents

Publications

  • Molin S, Baselga E, Navarro-Trivino FJ, Reguiai Z, Schepper S, Halpern J, Marcoux D, Su JC, Brzewski P, Antonsen SD, Hiort LC, Sohoel A, Thogersen P, Rubel D. Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial. Lancet Child Adolesc Health. 2026 Aug;10(8):552-561. doi: 10.1016/S2352-4642(26)00098-2. Epub 2026 Jun 3. PubMed 42235562 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2024, 28 months.

Results were first posted in Jul 2025, 6 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 2, 2022
StartActual
Jul 14, 2022
Primary completionActual
Dec 5, 2024
CompletionActual
Dec 17, 2024
Results first posted
Jul 2, 2025
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05355818
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Jul 14, 2022
Primary completion
Dec 5, 2024
Completion
Dec 17, 2024
Results posted
Jul 2, 2025
Last update
Aug 21, 2026

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion